Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CTRB1 | P17538 | 4/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.41 |
| ▸ | CTSG | P08311 | 3/20 | 0.41 |
| ▸ | CMA1 | P23946 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6859238 | 1.00 | LMNA (0.51) | LMNAHPGDHDAC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13621588 | 0.83 | LMNA (0.59) | LMNAHPGDHDAC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13048136 | 0.83 | LMNA (0.59) | LMNAHPGDHDAC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4185708 | 0.81 | LMNA (0.50) | LMNAHPGDHDAC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL14516389 | 0.79 | ALDH1A1 (0.49) | LMNAHPGDHDAC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL14574458 | 0.78 | LMNA (0.56) | LMNAHPGDHDAC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL14420891 | 0.77 | LMNA (0.59) | LMNAHPGDHDAC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13426750 | 0.77 | LMNA (0.59) | LMNAHPGDHDAC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL5089394 | 0.76 | LMNA (0.51) | LMNAHPGDHDAC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL14370539 | 0.76 | LMNA (0.51) | LMNAHPGDHDAC1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6784304-B2 | USE OF OPTIONALLY N-PROTECTED 2,2-DIALKYL,4-SUBSTITUTED-5-CARBOXY-OXADIAZOLIDINES IN THE PREPARATION OF C-13 ACYLOXY SIDECHAIN-BEARING TAXANES SUCH AS PACLITAXEL | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-31 | — | — | US | disclosed |
| US-20020161238-A1 | Novel methods for the preparation of taxanes using oxazolidine intermediates | THOTTATHIL JOHN K (US) | 2002-10-31 | — | — | US | disclosed |
| US-6365750-B1 | 5-OXAZOLIDINECARBOXYLIC ACIDS FOR THE PREPARATION OF C-13 ACYLOXY SIDE CHAIN BEARING TAXANES E.G PACLITAXEL; COUPLING WITH A C-13 HYDROXYTAXANE FOLLOWED BY DECYCLIZATION OF THE OXAZOLIDINE RING | BRISTOL MYERS SQUIBB COMP. | 2002-04-02 | — | — | US | disclosed |
| EP-0735036-A1 | Methods for the preparation of taxanes using oxazolidine intermediates | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161238-A1 | Novel methods for the preparation of taxanes using oxazolidine intermediates | TOP2A, TOP2B, CDK13 | LMNA 1990/4885HPGD 1594/4885HDAC1 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.